Clinical TrialJul 15, 2026, 07:31 AM
Acumen's ACU401 shows 40-fold brain penetration in non-human primates
AI Summary
Acumen Pharmaceuticals announced new findings at AAIC 2026, demonstrating significantly improved brain penetration of their EBD bispecific antibodies, particularly candidate ACU401, in non-human primates. This collaboration with JCR Pharmaceuticals showed up to 40-fold greater frontal cortex exposure and no hematological safety signals. Additionally, patient experience data from the ALTITUDE-AD trial underscored the unmet needs in early Alzheimer's disease, reinforcing the importance of Acumen's therapeutic development.
Key Highlights
- ACU401 achieved up to 40-fold greater frontal cortex exposure in non-human primates.
- Bispecific antibodies showed at least 14-fold higher brain levels than native anti-AβO antibodies.
- No hematological safety signals were observed in non-human primates.
- Acumen collaborated with JCR Pharmaceuticals on EBD candidate development.
- Patient experience data from ALTITUDE-AD highlighted unmet needs in early Alzheimer's disease.
- Sabirnetug (ACU193) is currently in a Phase 2 study (ALTITUDE-AD) with topline results expected late 2026.
Price Impact
More from ABOS